FindTrial
Sign In

Post Trial Access to Lucerastat for Patients With Fabry Disease Who Participated in Study ID-069A302

Status
AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT07762638
Enrollment
Unknown
Registered
2026-08-13
Start date
Unknown
Completion date
Unknown
Last updated
2026-08-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fabry Disease

Brief summary

This is a Post Trial Access program for patients with Fabry Disease who previously participated in the ID-069A302 (MODIFY OLE) trial and who were still enrolled in the study at the time the Sponsor decided to discontinue ID-069A302. The program is designed to provide continued access to lucerastat.

Interventions

DRUGLucerastat

Sponsors

Idorsia Pharmaceuticals Ltd.
Lead SponsorINDUSTRY

Eligibility

Inclusion criteria

\-

Exclusion criteria

\-

Contacts

CONTACTIdorsia Clinical Trials Information
idorsiaclinicaltrials@idorsia.com+1 856 661 37 21

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 14, 2026